In-detail Table of Contents of Hemophilia B Pipeline Market
Companies involved in this research Alnylam Pharmaceuticals, Inc., Amarna Therapeutics B.V., Baxalta Incorporated, Bayer AG, Biogen, Inc., Catalyst Biosciences, Inc., CSL Limited, Dimension Therapeutics, Inc., Emergent BioSolutions Inc., Novo Nordisk A/S, OPKO Health, Inc., Pfizer Inc., Pharming Group N.V., RegenxBio Inc., rEVO Biologics, Inc., Sangamo BioSciences, Inc., Spark Therapeutics, Inc. and UniQure N.V.
The report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects.
Scope for this research:
- The report provides a snapshot of the global therapeutic landscape of Hemophilia B
- The report reviews pipeline therapeutics for Hemophilia B by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hemophilia B therapeutics and enlists all their major and minor projects
- The report assesses Hemophilia B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hemophilia B
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
List of figures:
- Number of Products under Development for Hemophilia B, H1 2016
- Number of Products under Development for Hemophilia B - Comparative Analysis, H1 2016
- Number of Products under Development by Companies, H1 2016
- Number of Products under Investigation by Universities/Institutes, H1 2016
- Comparative Analysis by Late Stage Development, H1 2016
- Comparative Analysis by Clinical Stage Development, H1 2016
- Comparative Analysis by Early Stage Products, H1 2016
- Assessment by Monotherapy Products, H1 2016
- Number of Products by Targets, H1 2016
- Number of Products by Stage and Targets, H1 2016
- Number of Products by Mechanism of Actions, H1 2016
- Number of Products by Stage and Mechanism of Actions, H1 2016
- Number of Products by Routes of Administration, H1 2016
- Number of Products by Stage and Routes of Administration, H1 2016
- Number of Products by Molecule Types, H1 2016
- Number of Products by Stage and Molecule Types, H1 2016
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.